Navigation Links
Baron & Budd Attorney Denyse Clancy Speaks at International Mesothelioma Program's First Annual Harvard Medical School Course
Date:7/7/2008

DALLAS, July 7 /PRNewswire/ -- Denyse Clancy, an attorney and shareholder with the Dallas-based law firm Baron & Budd, P.C., spoke at the International Mesothelioma Program's First Annual Harvard Medical School Course, entitled Surgery-Based Multimodality Therapy for Malignant Pleural Mesothelioma. The program was held in Dallas on June 13 and 14.

The program was designed to update thoracic surgeons and other medical professionals about current diagnostic criteria and treatment options available for patients with pleural mesothelioma, a rare, asbestos-related cancer that attacks the lung's lining. It was co-sponsored by the American Association for Thoracic Surgery.

Ms. Clancy spoke with the group of medical professionals about how medical research articles are understood and applied in the courtroom -- sometimes in ways not intended by the scientist authors. Her words provoked lively discussion among the doctors and research scientists present, including questions about the scientific community's responsibility to anticipate the legal applications of their words.

Baron & Budd has a long-standing relationship with the International Mesothelioma Program (IMP). As a member of the IMP's Executive Advisory Board, the law firm is in regular contact with the IMP to remain abreast of mesothelioma research updates affecting treatment options. Baron & Budd was invited to become a member the Executive Board because of our experience and commitment to working with people with mesothelioma. Baron and Budd was the first and remains the longest-standing member of the IMP Executive Advisory Board.

About Baron & Budd, P.C.

Since 1977, the law firm of Baron & Budd, P.C. has championed the rights of people and communities harmed by corporate misconduct. With 49 attorneys and offices in Texas, California and Louisiana, Baron & Budd enjoys a national reputation as a leader of the plaintiffs' bar. The firm represents individuals with mesotheliom
'/>"/>

SOURCE Baron & Budd, P.C.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Asbestos Verdict Upheld by Louisiana Court of Appeal, Announces Baron & Budd
2. Former Texas Assistant Attorney General Pat OConnell Joins Baron & Budd, P.C., to Lead Whistleblower Litigation Practice
3. Baron & Budd, P.C., Announces $3.6 Million Settlement in California Asbestos Lawsuit
4. California Attorney Robert A. Brenner Launches The Burn Injury Law Group to Aid Burn Victims Nationwide
5. Blue Cross Blue Shield of Michigan Responds to Attorney Generals Complaint, Says Transaction Was Legal and Fully Authorized
6. L.A. City Attorney Rocky Delgadillo, Patient Activists to Unveil New Television Ad Targeting Health Insurers
7. Prepared Remarks of Attorney General Michael B. Mukasey on the Justice Departments Efforts to Combat Healthcare Fraud Nationwide
8. Attorney General Michael B. Mukasey to Deliver Keynote Address at Naturalization Ceremony and Remarks on Nationwide Efforts to Combat Healthcare Fraud
9. Pennsylvania Attorney General Corbett Announces Multi-State Settlement With Express Scripts Inc.
10. Pennsylvania Attorney General Corbett Announces a Multi-state, $58 Million Settlement With Merck Over Deceptive Advertising Concerning the Safety of Vioxx
11. Wage Complaint Forwarded to Attorney General for Prosecution
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Disrupting a destructive duo 3A U of T Mississauga researchers inhibit cancer proteins 9634 1Disrupting a destructive duo 3A U of T Mississauga researchers inhibit cancer proteins 9634 2Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 1Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 2Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 3Nostrils Compete to Relay Key Fragrance 54963 1Nostrils Compete to Relay Key Fragrance 54963 2